-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Mv3IFQna4t3YDcw5wnuOznip5usmiz/J3jTFMPj1kb4LfTh3LTc4QX2KPJNPHIiw 8XqTnTDqsEonfVfqswbNpg== 0000950123-09-009476.txt : 20090713 0000950123-09-009476.hdr.sgml : 20090713 20090526171733 ACCESSION NUMBER: 0000950123-09-009476 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20090526 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS INC CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 6 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 6 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 CORRESP 1 filename1.htm CORRESP
AMICUS THERAPEUTICS, INC.
6 Cedar Brook Drive
Cranbury, New Jersey 08512
May 26, 2009
Via EDGAR and Facsimile
United States Securities and Exchange Commission
Division of Corporate Finance
100 F Street, NE
Washington, D.C. 20549
Attention: Jeffrey R. Riedler
 
Re:   Amicus Therapeutics, Inc.
Registration Statement on Form S-3, as amended
File No. 333-158405
Ladies and Gentlemen:
     Pursuant to Rule 461 of the Securities Act of 1933, as amended, and Rule 12(b)-6 of the Securities Exchange Act of 1934, as amended, Amicus Therapeutics, Inc., a Delaware corporation (the “Company”), hereby requests that the effectiveness of the Company’s above-referenced Registration Statement on Form S-3, as amended, be accelerated to 5 p.m. Eastern Time on Tuesday, May 26, 2009 at 5 p.m., or as soon as practicable thereafter, unless you are orally or in writing notified to the contrary by the Company prior to such date and time.
     The Company hereby acknowledges that:
•   should the Securities and Exchange Commission (the “Commission”) or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
 
•   the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
 
•   the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
     Should you have any questions regarding this request, please do not hesitate to contact Julio E. Vega (617-951-8901) or Meerie M. Joung (617-951-8840) of Bingham McCutchen LLP.
     
 
  Sincerely,
 
  AMICUS THERAPEUTICS, INC.
 
  /s/ John. F. Crowley
 
John F. Crowley
Chief Executive Officer and President
     
cc:
  Julio E. Vega, Esq., Bingham McCutchen LLP
Meerie M. Joung, Esq., Bingham McCutchen LLP
Geoffrey Gilmore, Esq., Amicus Therapeutics, Inc.
Peter Macaluso, Esq., Amicus Therapeutics, Inc.

-----END PRIVACY-ENHANCED MESSAGE-----